Stockscreener 앱 받기
1.19
0.00%
0.00
시간 외 거래:
1.20
0.01
+0.84%
Bone Biologics Corp 주식(BBLG)의 최신 뉴스
Bone Biologics Corp (BBLGW) Quarterly 10-Q Report - Quartzy
Orthobiologics Market Is Expected To Reach a Revenue Of USD 11.7 Bn By 2033, at 5.7% CAGR: Dimension Market Research - OrthoSpineNews
Orthobiologics Market Is Expected To Reach a Revenue Of USD - GlobeNewswire
Learn to Evaluate (BBLGW) using the Charts - Stock Traders Daily
OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action - The Malaysian Reserve
Long Term Trading Analysis for (BBLGW) - Stock Traders Daily
Orthobiologics Global Market Analysis, Trends, Growth, Research And Forecast 2033 - openPR
Spine Biologics Market Report 2024Spine Biologics Market Trends And Share - openPR
BBLGBone Biologics Corp Latest Stock News & Market Updates - StockTitan
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors - StockTitan
Therealreal Inc (REAL) Recovers 161.90% From Low: Sitting In The Catbird Seat? - Stocks Register
BBLG’s 2023 Market Dance: Down -67.26% – Time to Invest? - The InvestChronicle
Stock Market Recap: Bone Biologics Corp (BBLG) Concludes at 1.48, a -6.92 Surge/Decline - The Dwinnex
Tetrous®Inc. Announces Issue of an Additional U.S. Patent Related to EnFix® Demineralized Bone Fiber Implants for Sports Medicine Surgical Procedures - OrthoSpineNews
TETROUS®, INC. ANNOUNCES ISSUE OF AN ADDITIONAL U.S. PATENT RELATED TO ENFIX® DEMINERALIZED BONE FIBER IMPLANTS FOR SPORTS MEDICINE SURGICAL PROCEDURES - PR Newswire
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.55% - MSN
Ortho Biological Products Market Giants Spending Is Going to Boom - Bacterial Vaccines Market with ...
Bone Biologics announces director resignation - Investing.com India
Bone Biologics announces director resignation By Investing.com - Investing.com South Africa
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.55% - MSN
Bone Void Fillers Market 2024By Industry Outlook, Future Trends, Growth Analysis And Forecast To 2033 - openPR
Was there any good news for Bone Biologics Corp (BBLG) stock in the last session? - US Post News
Bone Biologics Corp (BBLG) Stock: Navigating a Year of Volatility - The InvestChronicle
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga
In the Green: Bone Biologics Corp (BBLG) Closes at 1.52, Up/Down -26.92 from Previous Day - The Dwinnex
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.55% - MSN
Cutera (CUTR) Stock Drops 5.14% Amid Financial Challenges - GuruFocus.com
Bone Biologics (NASDAQ:BBLG) Stock Quotes, Forecast and News Summary - Benzinga
Orthobiologics Market Industry Analysis 2024 Future Scope, - openPR
A closer look at BBLG’s price-to-free cash flow ratio - US Post News
Bone Biologics Corp (BBLG) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Wall Street today: US stocks surge stops as investors pause after big US Fed rate cut, Nike gains 6.59% | Stock Market News - Mint
Bone Biologics Corp [BBLG] Is Currently 20.23 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Orthobiologics Market See Incredible Growth 2024-2031 | Zimmer - openPR
SLNO Skyrockets 800%, BWAY Blasts Past 400%Were You On Board? - RTTNews
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors - CNBC
BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update - MarketBeat
Bausch Reportedly Eyes A Sale; Could J&J Or AbbVie Buy It? - Investor's Business Daily
Nothing is Better Than Bone Biologics Corp (BBLG) stock at the moment - SETE News
Orthobiologics Market 2024 SWOT Analysis, Key Business Strategies by Leading Industry Players and Forecast 2033 - Cauverynews
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Reviewing BioLargo (NASDAQ:BLGO) and Loop Industries (NASDAQ:LOOP) - Defense World
Why Bausch + Lomb Rallied Today - The Motley Fool
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues - AOL
Bausch + Lomb Stock Jumps Amid Reports Of A Sale - Investopedia
BBLG’s price-to-free cash flow ratio: What it means for investors - US Post News
Bone Biologics Corp’s Banking’s 100-Day Moving Average at 1.5338: Will the Stock Break Through? - The InvestChronicle
Bone Biologics rises 5% on $2M equity offering - MSN
Bausch & Lomb shares jump on spin-off sale hopes - ShareCast
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
M&A News: Bausch+Lomb (NYSE:BLCO) Potentially Exploring Sale Amid Parent Company’s Debt Struggles - TipRanks
Daily Progress: Bone Biologics Corp (BBLG) Drop -32.77, Closing at 0.80 - The Dwinnex
Bausch + Lomb explores sale amid parent company's debt woesreport By Investing.com - Investing.com Canada
Bausch + Lomb eyeing sale amid spinoff concerns (NYSE:BLCO) - Seeking Alpha
BBLG stock touches 52-week low at $1 amid steep annual decline - Investing.com
Financial Analysis: Sanara MedTech (NASDAQ:SMTI) vs. Bone Biologics (NASDAQ:BBLG) - Defense World
Spine Biologics Market Size to Achieve USD 6.95 Bn by 2033 - GlobeNewswire
1.38%
0.43%
자본화:
|
볼륨(24시간):